Veru (VERU) versus Its Competitors Financial Comparison

Veru (NASDAQ:VERU) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Veru to related businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Profitability

This table compares Veru and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Veru Competitors	-2,372.59%	-220.82%	-15.99%

Institutional & Insider Ownership

47.2% of Veru shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Veru and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1	0	3	0	2.50
Veru Competitors	7792	13886	25777	1037	2.41

Veru presently has a consensus price target of $24.50, indicating a potential upside of 1,055.66%. As a group, “Pharmaceuticals” companies have a potential upside of 25.56%. Given Veru’s stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than its peers.

Risk and Volatility

Veru has a beta of -1.2, meaning that its stock price is 220% less volatile than the S&P 500. Comparatively, Veru’s peers have a beta of -4.04, meaning that their average stock price is 504% less volatile than the S&P 500.

Earnings and Valuation

This table compares Veru and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Veru	$16.89 million	-$22.73 million	-3.07
Veru Competitors	$3.54 billion	$3.17 billion	554.50

Veru’s peers have higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Veru beats its peers on 8 of the 13 factors compared.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.